Plate Nº 37 · recorded October 10, 2026
Health & Medicine ResearchReported finding
Phase 3 Trial Tests Baxdrostat Against Resistant Hypertension
The Lancet publishes Bax24, a phase 3 randomised trial testing whether baxdrostat lowers 24-hour blood pressure in patients with resistant hypertension.
By Marcus Bennett2 min read407 words
In brief
- The Lancet published Bax24, a phase 3 trial of baxdrostat in resistant hypertension.
- The trial was randomised, double-blind, and placebo-controlled.
- The primary measure was 24-hour ambulatory blood pressure.
- Resistant hypertension means blood pressure stays high despite at least three medications.
- Baxdrostat targets the aldosterone hormone pathway.
A phase 3 trial published in The Lancet has evaluated whether baxdrostat can lower ambulatory blood pressure in patients with resistant hypertension — a condition that standard three-drug treatment fails to control.
The study, named Bax24, appears in one of medicine's most influential journals, and its design reflects the highest bar for clinical evidence.
What did the trial test?
Baxdrostat is an investigational drug that targets aldosterone, a hormone produced by the adrenal glands that regulates salt and water balance in the body. When aldosterone activity runs too high, blood pressure climbs.
The trial enrolled patients with resistant hypertension. That means their blood pressure stayed above target even though they were already taking at least three antihypertensive medications, typically including a diuretic.
How was the study designed?
Bax24 was a phase 3 trial — the late stage of human testing that regulators such as the FDA require before approving a new medicine. Three features made the evidence robust:
- Randomisation: participants were assigned by chance to receive either baxdrostat or a placebo, which prevents selection bias.
- Double-blinding: neither the patients nor the researchers knew who received the active drug until the trial ended.
- Placebo control: the drug's performance was measured against an inert pill, so any difference reflects the treatment itself.
Why measure ambulatory blood pressure?
Rather than relying on single office readings, the researchers tracked ambulatory blood pressure — measurements taken automatically throughout a full 24-hour period while patients went about their daily lives.
This method captures nighttime values and daily fluctuations. Doctors consider it a more reliable predictor of cardiovascular risk than one-off clinic measurements, which can be distorted by the stress of a medical visit.
Why does resistant hypertension matter?
Patients whose blood pressure resists three or more medications face elevated risks of:
- heart attack,
- stroke,
- kidney damage.
A drug that works through a different biological pathway could give these patients an option when existing combinations fall short. Baxdrostat's aldosterone-targeting mechanism differs from how most standard blood pressure drugs act.
What should readers keep in mind?
The Lancet publication marks a milestone, but several cautions apply.
As with any single trial, the results describe what researchers observed in this specific study population. Whether baxdrostat ultimately reaches patients depends on regulatory review, which weighs efficacy together with safety data across all trials.
Full results, including exact blood pressure reductions and side-effect profiles, appear in the published paper in The Lancet.
via Google News: Clinical Trials (Source)
More from Marcus Bennett
Show full bio
News editor covering regulation, policy and their impact on general science news at SciBeat.
261 articles
Nearby plates
- Retatrutide Succeeds in Two More Phase 3 Obesity Trials, Lilly Reports
- Retatrutide Delivers Up to 71.2 Lbs Weight Loss in Phase 3
- Lilly's Retatrutid Cuts Blood Sugar and Weight in First Phase 3 Trial
- AstraZeneca and Ionis Heart Drug Fails Major Study
- ATTAIN-MAINTAIN Trial Tests Orforglipron for Sustained Weight Loss